Academic Journal
Cost-effectiveness analysis of NEPA, a fixed-dose combination of netupitant and palonosetron, for the prevention of highly emetogenic chemotherapy-induced nausea and vomiting: an international perspective
| العنوان: | Cost-effectiveness analysis of NEPA, a fixed-dose combination of netupitant and palonosetron, for the prevention of highly emetogenic chemotherapy-induced nausea and vomiting: an international perspective |
|---|---|
| المؤلفون: | Nilsson, Jonas, Piovesana, Vittoria, Turini, Marco, Lezzi, Claudio, Eriksson, Jennifer, Aapro, Matti |
| المصدر: | Supportive Care in Cancer ; volume 30, issue 11, page 9307-9315 ; ISSN 0941-4355 1433-7339 |
| بيانات النشر: | Springer Science and Business Media LLC |
| سنة النشر: | 2022 |
| الوصف: | Purpose The aim of this study was to assess the cost-effectiveness of NEPA, a fixed-dose combination of oral netupitant (300 mg) and palonosetron (0.5 mg), compared to available treatments in Spain after aprepitant generic introduction in the market, and to discuss results in previously performed analyses in different wordwide settings. Methods A Markov model including three health states, complete protection, complete response at best and incomplete response, was used to evaluate the cost-effectiveness of NEPA versus common treatment options in Spain during 5 days after chemotherapy. Incremental costs including treatment costs and treatment failure management cost as well as incremental effects including quality adjusted life days (QALDs) and emesis-free days were compared between NEPA and the comparator arms. The primary outcomes were cost per avoided emetic event and cost per QALDs gained. Results NEPA was dominant (more effective and less costly) against aprepitant combined with palonosetron, and fosaprepitant combined with granisetron, while, compared to generic aprepitant plus ondansetron, NEPA showed an incremental cost per avoided emetic event of €33 and cost per QALD gained of €125. Conclusion By most evaluations, NEPA is a dominant or cost-effective treatment alternative to current antiemetic standards of care in Spain during the first 5 days of chemotherapy treatment in cancer patients, despite the introduction of generics. These results are in line with previously reported analyses throughout different international settings. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1007/s00520-022-07339-1 |
| DOI: | 10.1007/s00520-022-07339-1.pdf |
| DOI: | 10.1007/s00520-022-07339-1/fulltext.html |
| الاتاحة: | http://dx.doi.org/10.1007/s00520-022-07339-1 https://link.springer.com/content/pdf/10.1007/s00520-022-07339-1.pdf https://link.springer.com/article/10.1007/s00520-022-07339-1/fulltext.html |
| Rights: | https://creativecommons.org/licenses/by/4.0 ; https://creativecommons.org/licenses/by/4.0 |
| رقم الانضمام: | edsbas.AEF48E3A |
| قاعدة البيانات: | BASE |
| DOI: | 10.1007/s00520-022-07339-1 |
|---|